TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07103018: A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Sponsor: K36 Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 144 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07103018 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07103018 Rescue Dossier →